It was a good week for the healthcare sector. Medical tourism is growing in Tijuana, INCan launches new model of attention and current Minister of Health calls for more investment. In less positive news, Mexican software company reveals it left personal data of millions of Mexicans exposed.
Innovative medicines also had a good week, with the FDA approving the first ever therapy based in RNA interference and Novartis, Pfizer and Takeda investing in the research pipelines of smaller companies.
This week Mexico Health Review spoke with Bupa Global’s Luk Vanderstede about the benefits of insurance, preventive care and the products his company offers.
Now, jump into this week’s highlights:
Medical tourism grows in Tijuana, motivating the city to invest in more infrastructure to receive the growing number of visitors.
INCan launches new model for the integral attention of locally-advanced cervical uterine cancer named Micaela.
José Narro, current Minister of Health, asks President-elect López Obrador to invest more in healthcare.
Mexican company Hova Health, a software provider for the Government of Michoacan, left private medical information on 2 million people exposed.
FDA approves Onpattro, the first ever therapy based on RNA interference. This drug will treat peripheral nerve disease (polyneuropathy) caused by a rare disease called transthyretin-mediated amyloidosis.
Pfizer and Novartis back Artios with US$84 million to develop DNA damage repair therapy.
Takeda Pharmaceutical invests US$80 million to support Ambys (a company named after the Mexican salamander, Ambystoma mexicanum) research line in regenerative medicine.